CClinicalTrials.gg
CompletedNCT05970471IMPLICATIONUpdated Dec 12, 2025

Preferences of Patients Treated With Oral Cancer Drugs and Informal Caregivers for Pharmaceutical Consultation in Hospital

An observational study in Preference, Patient, Pharmacist-Patient Relations and Caregiver, sponsored by Centre Hospitalier Universitaire de Besancon. Completed at 1 site in France. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-12.

Sponsored by Centre Hospitalier Universitaire de Besancon · Observational

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
167
Ages
18 Years and older
Sex
All
01

Study summary

To ensure the safe use of oral anticancer drugs, oncology pharmacy consultations (OPCs) have been established in France. Their goal is to provide the patient with the means to identify, prevent and limit adverse effects and to know who to refer to in case of a serious adverse effect, perform a pharmaceutical analysis of the prescription, and participate in the improvement and evaluation of overall compliance. OPCs are conditioned by the needs, expectations, and involvement of the patients in their care. In healthcare, patients are increasingly encouraged to play an active role in the knowledge and management of their health, express their concerns and preferences, and participate in medical decisions. Thus, it is essential to elicit their preferences. The discrete-choice experiment (DCE) is the validated and recommended method of the International Society for Pharmacoeconomics and Outcomes Research for such a task.

Read the detailed description

To ensure the safe use of oral anticancer drugs, oncology pharmacy consultations (OPCs) have been established in France. Their goal is to provide the patient with the means to identify, prevent and limit adverse effects and to know who to refer to in case of a serious adverse effect, perform a pharmaceutical analysis of the prescription, and participate in the improvement and evaluation of overall compliance. OPCs are conditioned by the needs, expectations, and involvement of the patients in their care. In healthcare, patients are increasingly encouraged to play an active role in the knowledge and management of their health, express their concerns and preferences, and participate in medical decisions. Thus, it is essential to elicit their preferences. The discrete-choice experiment (DCE) is the validated and recommended method of the International Society for Pharmacoeconomics and Outcomes Research for such a task.

02

Conditions studied

  • Preference, Patient
  • Pharmacist-Patient Relations
  • Caregiver
  • Cancer

Keywords

  • Preference, Patient
  • Pharmacist-Patient Relations
  • Cancer of Colon
  • Cancer, Breast
  • Lung Cancer
  • Prostate Cancer
  • Renal Cancer
  • caregiver
03

In context

Patient Preference

33 studies on the registry are indexed under Patient Preference; 17 are open to participants now.

This study's enrollment of 167 is below the median of 202 across 15 observational studies indexed under Patient Preference.

Browse Patient Preference studies →

Lead sponsor

Centre Hospitalier Universitaire de Besancon is the lead sponsor of 439 studies on the registry; 97 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

240 patients - 60 Caregivers - 360 healhcare professionnals (pharmacist, oncologists, general practitioners)

Eligibility criteria

of patients:

Main inclusion Criteria:

  • Patients with lung, prostate breast, prostate or renal cancer;
  • Patients with oral cancer drugs;
  • Patients accepted to take par in pharmaceutical consultation in hospital.
05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
167 participants (actual)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Preferences of patients

    utility associated with each attribute

    Time frame: 12 months

Secondary outcomes

  1. Preferences of cargivers and healthcare profesionnals

    utility associated with each attribute

    Time frame: 12 months

07

Study locations

1 site
  • CHU de Besançon
    Besançon, 25030, France
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05970471
Lead sponsor
Centre Hospitalier Universitaire de Besancon
Responsible party
Sponsor
First posted
Aug 1, 2023
Start date
Aug 10, 2023
Primary completion
Dec 4, 2025
Completion
Dec 4, 2025
Last update
Dec 12, 2025

Study contacts

Virginie NERICH, PhD
principal investigator · CHU de Besançon

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion